仟源医药: 国浩律师（上海）事务所关于仟源医药2025年第二次临时股东会之法律意见书

Core Viewpoint - The legal opinion letter from Grandall Law Firm confirms that the procedures for the second extraordinary general meeting of shareholders of Shanxi Qianyuan Pharmaceutical Group Co., Ltd. are in compliance with relevant laws and regulations, ensuring the legality and validity of the meeting and its resolutions [1][8]. Group 1: Meeting Procedures - The board of directors convened on May 26, 2025, to approve the proposal for the second extraordinary general meeting of shareholders, which is scheduled for June 11, 2025 [4]. - The notice for the meeting was published on May 27, 2025, detailing the meeting's basic information, including the date, location, and voting procedures [4][5]. - The meeting will include both on-site and online voting arrangements for shareholders [5]. Group 2: Attendance and Voting - As of the record date, the total number of shares with voting rights is 248,318,563 [6]. - A total of 108 shareholders and their proxies attended the meeting, representing 31,074,666 shares, which is 12.5140% of the total voting shares [6]. - The qualifications of the attendees were verified and deemed valid according to legal and regulatory requirements [6]. Group 3: Resolutions and Voting Results - The meeting reviewed and voted on several proposals, with the first proposal requiring a special resolution [7]. - The voting results showed that 30,918,846 shares approved the first proposal, and 30,887,546 shares approved the second proposal, indicating a strong majority [7]. - The voting procedures were conducted in accordance with legal requirements, and the results were confirmed as valid [8].